Stories of Life With Esophageal Cancer: Roger, Ellen, and Jeff

Patients treated with ide-cel, Abecma for relapsed/refractory multiple myeloma affecting the central nervous system had similar outcomes to matched patients with non-CNS multiple myeloma.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

New data from the ZUMA-2 trial of brexu-cel showed an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors.

Sattva S. Neelapu, MD, notes that axi-cel is a highly effective therapeutic approach for patients with relapsed/refractory indolent non-Hodgkin lymphoma.